{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:09:33Z","timestamp":1783714173567,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Trace Elem Res"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12011-021-02802-2","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T02:02:49Z","timestamp":1624932169000},"page":"1608-1616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax\/Bcl-2 Ratio in HL-60 Cell Line"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-9150","authenticated-orcid":false,"given":"Tu\u011fba","family":"Erkmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4118-5964","authenticated-orcid":false,"given":"Belgin Sert","family":"Serdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-5586","authenticated-orcid":false,"given":"Mehmet","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-1845","authenticated-orcid":false,"given":"Semra","family":"Ko\u00e7t\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"key":"2802_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"12","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 12:1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"issue":"1","key":"2802_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA: Cancer J Clin 65(1):5\u201329. https:\/\/doi.org\/10.3322\/caac.21254","journal-title":"CA: Cancer J Clin"},{"key":"2802_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.beha.2018.09.005","volume":"31","author":"JE Lancet","year":"2018","unstructured":"Lancet JE (2018) Is the overall survival for older adults with AML finally improving? Best Pract Res Clin Haematol 31:387\u2013390. https:\/\/doi.org\/10.1016\/j.beha.2018.09.005","journal-title":"Best Pract Res Clin Haematol"},{"key":"2802_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K (2020) The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study. J Hematol Oncol 13:1\u201316. https:\/\/doi.org\/10.1186\/s13045-020-00908-z","journal-title":"J Hematol Oncol"},{"key":"2802_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3324\/haematol.10279","volume":"92","author":"U Testa","year":"2007","unstructured":"Testa U, Riccioni R (2007) Deregulation of apoptosis in acute myeloid leukemia. Haematologica 92:81\u201394. https:\/\/doi.org\/10.3324\/haematol.10279","journal-title":"Haematologica"},{"key":"2802_CR7","doi-asserted-by":"publisher","unstructured":"Hanahan D, Weinberg RA (2016). Biological hallmarks of cancer. Holland\u2010Frei Cancer Medicine 1-10. https:\/\/doi.org\/10.1002\/9781119000822.hfcm002","DOI":"10.1002\/9781119000822.hfcm002"},{"key":"2802_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nature17403","volume":"532","author":"L Seifert","year":"2016","unstructured":"Seifert L, Werba G, Tiwari S, Ly NNG, Alothman S, Alqunaibit D et al (2016) The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532:245\u2013249. https:\/\/doi.org\/10.1038\/nature17403","journal-title":"Nature"},{"key":"2802_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17:395\u2013417","journal-title":"Nat Rev Clin Oncol"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","volume":"179","author":"GFS Fernandes","year":"2019","unstructured":"Fernandes GFS, Denny WA, Dos Santos JL (2019) Boron in drug design: recent advances in the development of new therapeutic agents. Eur J Med Chem 179:791\u2013804. https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.092","journal-title":"Eur J Med Chem"},{"key":"2802_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02783135","volume":"66","author":"PD Howe","year":"1998","unstructured":"Howe PD (1998) A review of boron effects in the environment. Biol Trace Elem Res 66:153\u2013166","journal-title":"Biol Trace Elem Res"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF02916650","volume":"22","author":"CD Hunt","year":"1989","unstructured":"Hunt CD (1989) Dietary boron modified the effects of magnesium and molybdenum on mineral metabolism in the cholecalciferol- deficient chick. Biol Trace Elem Res 22:201\u2013220","journal-title":"Biol Trace Elem Res"},{"key":"2802_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF02990471","volume":"28","author":"M Hegsted","year":"1991","unstructured":"Hegsted M, Keenan MJ, Siver F, Wozniak P (1991) Effect of boron on vitamin D deficient rats. Biol Trace Elem Res 28:243\u2013255","journal-title":"Biol Trace Elem Res"},{"key":"2802_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/A:1004276311956","volume":"193","author":"FH Nielsen","year":"1997","unstructured":"Nielsen FH (1997) Boron in human and animal nutrition. Plant Soil 193:199\u2013208","journal-title":"Plant Soil"},{"key":"2802_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02783140","volume":"66","author":"S Samman","year":"1998","unstructured":"Samman S, Naghii MR, Lyons Wall PM, Verus AP (1998) The nutritional and metabolic effects of boron in humans and animals. Biol Trace Elem Res 66:227\u2013235","journal-title":"Biol Trace Elem Res"},{"key":"2802_CR16","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1242\/jeb.202.12.1649","volume":"202","author":"RI Rowe","year":"1999","unstructured":"Rowe RI, Eckhert CD (1999) Boron is required for zebrafish embryogenesis. J Exp Biol 202:1649\u20131654","journal-title":"J Exp Biol"},{"key":"2802_CR17","first-page":"1512","volume":"12","author":"A Basoglu","year":"2011","unstructured":"Basoglu A, Baspinar N, Ozturk AS, Akalin PP (2011) Effects of long-term boron administration on high-energy diet-induced obesity in rabbits: NMR-based metabonomic evaluation. J Anim and Veterinary Adv 12:1512\u20131515","journal-title":"J Anim and Veterinary Adv"},{"key":"2802_CR18","first-page":"419","volume":"163","author":"M Kabu","year":"2012","unstructured":"Kabu M, Civelek T (2012) Effects of propylene glycol, methionine and sodium borate on metabolic profile in dairy cattle during periparturient period. Revue M\u00e9d V\u00e9t 163:419\u2013430","journal-title":"Revue M\u00e9d V\u00e9t"},{"key":"2802_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jtemb.2012.03.014","volume":"26","author":"CD Hunt","year":"2012","unstructured":"Hunt CD (2012) Dietary boron: progress in establishing essential roles in human physiology. J Trace Elements in Med and Biol 26:157\u2013160","journal-title":"J Trace Elements in Med and Biol"},{"key":"2802_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/pros.10166","volume":"54","author":"MT Gallardo-Williams","year":"2003","unstructured":"Gallardo-Williams MT, Maronpot RR, Wine RN, Brunssen SH, Chapin RE (2003) Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid. Prostate 54:44\u201349. https:\/\/doi.org\/10.1002\/pros.10166","journal-title":"Prostate"},{"key":"2802_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/2156587211407638","volume":"16","author":"FH Nielsen","year":"2011","unstructured":"Nielsen FH, Meacham SL (2011) Growing evidence for human health benefits of boron. J Evid-Based Complement Alternat Med 16:169\u2013180. https:\/\/doi.org\/10.1177\/2156587211407638","journal-title":"J Evid-Based Complement Alternat Med"},{"key":"2802_CR22","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s13277-013-1212-2","volume":"35","author":"M Korkmaz","year":"2014","unstructured":"Korkmaz M, Avc\u0131 CB, Gunduz C, Aygunes D, Erbaykent-Tepedelen B (2014) Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells. Tumor Biol 35:1531\u20131538. https:\/\/doi.org\/10.1007\/s13277-013-1212-2","journal-title":"Tumor Biol"},{"key":"2802_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/17460441.2016.1174687","volume":"11","author":"ZJ Le\u015bnikowski","year":"2016","unstructured":"Le\u015bnikowski ZJ (2016) Recent developments with boron as a platform for novel drug design. Expert Opin Drug Discov 11:569\u2013578. https:\/\/doi.org\/10.1080\/17460441.2016.1174687","journal-title":"Expert Opin Drug Discov"},{"key":"2802_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cmdc.201500199","volume":"11","author":"W Neumann","year":"2016","unstructured":"Neumann W, Xu S, S\u00e1rosi MB, Scholz MS, Crews BC, Ghebreselasie K, Hey-Hawkins E (2016) nido-Dicarbaborate induces potent and selective inhibition of cyclooxygenase-2. ChemMedChem 11:175\u2013178. https:\/\/doi.org\/10.1002\/cmdc.201500199","journal-title":"ChemMedChem"},{"key":"2802_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1006\/bbrc.2000.2440","volume":"270","author":"A Dibas","year":"2000","unstructured":"Dibas A, Howard J, Anwar S, Stewart D, Khan A (2000) Borato-1, 2-diaminocyclohexane platinum (II), a novel anti-tumor drug. Biochem Biophys Res Commun 270:383\u2013386. https:\/\/doi.org\/10.1006\/bbrc.2000.2440","journal-title":"Biochem Biophys Res Commun"},{"key":"2802_CR26","doi-asserted-by":"publisher","first-page":"11280","DOI":"10.1021\/acs.jafc.7b04069","volume":"65","author":"E Jin","year":"2017","unstructured":"Jin E, Ren M, Liu W, Liang S, Hu Q, Gu Y, Li S (2017) Effect of boron on thymic cytokine expression, hormone secretion, antioxidant functions, cell proliferation, and apoptosis potential via the extracellular signal-regulated kinases 1 and 2 signaling pathway. J Agric Food Chem 65:11280\u201311291. https:\/\/doi.org\/10.1021\/acs.jafc.7b04069","journal-title":"J Agric Food Chem"},{"key":"2802_CR27","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1021\/acsanm.9b02486","volume":"3","author":"M Emanet Ciofani","year":"2020","unstructured":"Emanet Ciofani M, Sen O, \u00c7ulha M (2020) Hexagonal boron nitride nanoparticles for prostate cancer treatment. ACS Applied Nano Mater 3:2364\u20132372. https:\/\/doi.org\/10.1021\/acsanm.9b02486","journal-title":"ACS Applied Nano Mater"},{"key":"2802_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.14740\/wjon1296","volume":"11","author":"H Tatebe","year":"2020","unstructured":"Tatebe H, Masunaga SI, Nishimura Y (2020) Effect of rapamycin on the radio-sensitivity of cultured tumor cells following boron neutron capture reaction. World Journal of Oncology. 11:158. https:\/\/doi.org\/10.14740\/wjon1296","journal-title":"World Journal of Oncology."},{"key":"2802_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s0960-894x(98)00029-8","volume":"8","author":"J Adams","year":"1998","unstructured":"Adams J, Behnke M, Chen S, Cruickshank AA et al (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333\u2013338. https:\/\/doi.org\/10.1016\/s0960-894x(98)00029-8","journal-title":"Bioorg Med Chem Lett"},{"key":"2802_CR30","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1126\/science.1142189","volume":"316","author":"FL Rock","year":"2007","unstructured":"Rock FL, Mao W, Yaremchuk A, Tukalo M et al (2007) An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759\u20131761. https:\/\/doi.org\/10.1126\/science.1142189","journal-title":"Science"},{"key":"2802_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.bmcl.2009.03.007","volume":"19","author":"T Akama","year":"2009","unstructured":"Akama T, Baker SJ, Zhang JK, Hernandez V, Zhou H, Sanders V et al (2009) Discovery and structure\u2013activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 19:2129\u20132132. https:\/\/doi.org\/10.1016\/j.bmcl.2009.03.007","journal-title":"Bioorg Med Chem Lett"},{"key":"2802_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL et al (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75:494\u2013503. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.046","journal-title":"J Am Acad Dermatol"},{"key":"2802_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508\u2013513","journal-title":"Oncologist"},{"key":"2802_CR34","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ncb0805-766","volume":"7","author":"B Meusser","year":"2005","unstructured":"Meusser B, Hirsch C, Jarosch E, Sommer T (2005) ERAD: the long road to destruction. Nat Cell Biol 7:766\u2013772","journal-title":"Nat Cell Biol"},{"key":"2802_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","volume":"46","author":"PM Voorhees","year":"2006","unstructured":"Voorhees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46:189\u2013213","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2802_CR36","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12:2955\u20132960","journal-title":"Clin Cancer Res"},{"key":"2802_CR37","first-page":"135","volume":"8","author":"L Raedler","year":"2015","unstructured":"Raedler L (2015) Velcade (bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma. Am Health Drug Benefits 8:135\u2013140","journal-title":"Am Health Drug Benefits"},{"key":"2802_CR38","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649\u20131657","journal-title":"Clin Cancer Res"},{"key":"2802_CR39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T R\u00fcckrich","year":"2009","unstructured":"R\u00fcckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M et al (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23:1098\u20131105","journal-title":"Leukemia"},{"key":"2802_CR40","first-page":"705714","volume":"2013","author":"C Sarlo","year":"2013","unstructured":"Sarlo C, Buccisano F, Maurillo L, Cefalo M, di Caprio L, Cicconi L et al (2013) Phase II study of bortezomib as a single agent in patients with previously untreated or relapsed\/refractory acute myeloid leukemia ineligible for intensive therapy. Leuk Res Treatment 2013:705714","journal-title":"Leuk Res Treatment"},{"key":"2802_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","volume":"31","author":"EC Attar","year":"2013","unstructured":"Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ et al (2013) Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study. J Clin Oncol 31:923\u2013929","journal-title":"J Clin Oncol"},{"key":"2802_CR42","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3109\/10428194.2013.833333","volume":"55","author":"AR Walker","year":"2014","unstructured":"Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM et al (2014) Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 55:1304\u20131308","journal-title":"Leuk Lymphoma"},{"key":"2802_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"4","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T (2018) Drug resistance in multiple myeloma. Cancer Treat Rev 4:199\u2013208","journal-title":"Cancer Treat Rev"},{"key":"2802_CR44","first-page":"511","volume":"20","author":"N Murmu","year":"2001","unstructured":"Murmu N, Mitra S, Das M, Gomes A, Vedasiromoni JR, Ghosh M, Bhattacharya M, Ghosh P, Biswas J, Bhattacharya S, Sur P (2001) Boron compounds against human leukemic cells. J Exp Clin Cancer Res 20:511\u2013515","journal-title":"J Exp Clin Cancer Res"},{"key":"2802_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2004.06.001","volume":"216","author":"WT Barranco","year":"2004","unstructured":"Barranco WT, Eckhert CD (2004) Boric acid inhibits human prostate cancer cell proliferation. Cancer Lett 216:21\u201329. https:\/\/doi.org\/10.1016\/j.canlet.2004.06.001","journal-title":"Cancer Lett"},{"key":"2802_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12011-007-8081-8","volume":"122","author":"R Scorei","year":"2008","unstructured":"Scorei R, Ciubar R, Ciofrangeanu CM, Mitran V, Cimpean A, Iordachescu D (2008) Comparative effects of boric acid and calcium fructoborate on breast cancer cells. Biol Trace Elem Res 122:197\u2013205. https:\/\/doi.org\/10.1007\/s12011-007-8081-8","journal-title":"Biol Trace Elem Res"},{"key":"2802_CR47","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/cmdc.201402075","volume":"9","author":"K Scarbaci","year":"2014","unstructured":"Scarbaci K, Troiano V, Ettari R, Pinto A, Micale N, Di Giovanni C, Grasso S (2014) Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents. ChemMedChem 9:1801\u20131816","journal-title":"ChemMedChem"},{"key":"2802_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10616-014-9755-7","volume":"68","author":"Z Cant\u00fcrk","year":"2016","unstructured":"Cant\u00fcrk Z, Tunali Y, Korkmaz S, Gulba\u015f Z (2016) Cytotoxic and apoptotic effects of boron compounds on leukemia cell line. Cytotechnology 68:87\u201393","journal-title":"Cytotechnology"},{"key":"2802_CR49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1039\/C8OB02668H","volume":"17","author":"M Lei","year":"2019","unstructured":"Lei M, Feng H, Bai E, Zhou H, Wang J, Qin Y et al (2019) Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer. Org Biomol Chem 17:683\u2013691","journal-title":"Org Biomol Chem"},{"key":"2802_CR50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s12011-019-01739-x","volume":"193","author":"C Hacioglu","year":"2020","unstructured":"Hacioglu C, Kar F, Kacar S, Sahinturk V, Kanbak G (2020) High concentrations of boric acid trigger concentration-dependent oxidative stress, apoptotic pathways and morphological alterations in DU-145 human prostate cancer cell line. Biol Trace Elem Res 193:400\u2013409. https:\/\/doi.org\/10.1007\/s12011-019-01739-x","journal-title":"Biol Trace Elem Res"},{"key":"2802_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4238\/gmr.15028300","volume":"15","author":"Y Wei","year":"2016","unstructured":"Wei Y, Yuan FJ, Zhou WB, Wu L, Chen L, Wang JJ, Zhang YS (2016) Borax-induced apoptosis in HepG2 cells involves p53, Bcl-2, and Bax. Genet Mol Res 15:2. https:\/\/doi.org\/10.4238\/gmr.15028300","journal-title":"Genet Mol Res"},{"key":"2802_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3892\/or.2019.7169","volume":"42","author":"L Wu","year":"2019","unstructured":"Wu L, Wei Y, Zhou WB, Zhang YS, Chen QH, Liu MX, Tang ZG (2019) Gene expression alterations of human liver cancer cells following borax exposure. Oncol Rep 42:115\u2013130. https:\/\/doi.org\/10.3892\/or.2019.7169","journal-title":"Oncol Rep"},{"key":"2802_CR53","doi-asserted-by":"publisher","first-page":"15501","DOI":"10.1021\/ja406406h","volume":"135","author":"S Deshayes","year":"2013","unstructured":"Deshayes S, Cabral H, Ishii T, Miura Y, Kobayashi S, Yamashita T, Matsumoto A, Miyahara Y, Nishiyama N, Kataoka K (2013) Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors. J Am Chem Soc 135:15501\u201315507. https:\/\/doi.org\/10.1021\/ja406406h","journal-title":"J Am Chem Soc"},{"key":"2802_CR54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ejmech.2016.10.023","volume":"125","author":"LQ Han","year":"2017","unstructured":"Han LQ, Yuan X, Wu XY, Li RD, Xu B, Cheng Q, Li RT (2017) Urea-containing peptide boronic acids as potent proteasome inhibitors. Eur J Med Chem 125:925\u2013939","journal-title":"Eur J Med Chem"},{"key":"2802_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2014.06.017","volume":"83","author":"V Troiano","year":"2014","unstructured":"Troiano V, Scarbaci K, Ettari R, Micale N, Cerchia C, Pinto A et al (2014) Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Eur J Med Chem 83:1\u201314","journal-title":"Eur J Med Chem"},{"key":"2802_CR56","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejmech.2017.01.034","volume":"128","author":"Y Ge","year":"2017","unstructured":"Ge Y, Li A, Wu J, Feng H, Wang L, Liu H, Li Y (2017) Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors. Eur J Med Chem 128:180\u2013191","journal-title":"Eur J Med Chem"},{"key":"2802_CR57","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bmc.2018.01.017","volume":"26","author":"H Liu","year":"2018","unstructured":"Liu H, Wu J, Ge Y, Li A, Li J, Liu Z, Li Y (2018) Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors. Bioorg Med Chem 26:1050\u20131061","journal-title":"Bioorg Med Chem"},{"key":"2802_CR58","doi-asserted-by":"publisher","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","volume":"59","author":"J Liu","year":"2016","unstructured":"Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Wang G (2016) Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD). J Med Chem 59:8134\u20138140","journal-title":"J Med Chem"},{"key":"2802_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10637-018-0611-z","volume":"37","author":"M Psurski","year":"2019","unstructured":"Psurski M, \u0141upicka-S\u0142owik A, Adamczyk-Wo\u017aniak A, Wietrzyk J, Sporzy\u0144ski A (2019) Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology\u2013phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells. Invest New Drugs 37:35\u201346","journal-title":"Invest New Drugs"},{"key":"2802_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5606\/fng.btd.2016.019","volume":"2","author":"\u00c7B Avc\u0131","year":"2016","unstructured":"Avc\u0131 \u00c7B, Erbaykent Tepedelen B, \u00d6zalp \u00d6, G\u00f6ker Ba\u011fca B, Dodurga Y, Ayg\u00fcne\u015f D, G\u00fcnd\u00fcz C (2016) Disodium pentaborate decahydrate up-regulates expressions of MAP kinase genes in human prostate cancer cells. FNG 2:100\u2013104. https:\/\/doi.org\/10.5606\/fng.btd.2016.019","journal-title":"FNG"},{"key":"2802_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-811X-8-31","volume":"8","author":"GV Chaitanya","year":"2010","unstructured":"Chaitanya GV, Alexander JS, Babu PP (2010) PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 8:1\u201311","journal-title":"Cell Commun Signal"},{"key":"2802_CR62","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrc1560","volume":"5","author":"JM Brown","year":"2005","unstructured":"Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231\u2013237. https:\/\/doi.org\/10.1038\/nrc1560","journal-title":"Nat Rev Cancer"},{"key":"2802_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.semcancer.2017.08.005","volume":"46","author":"V Curti","year":"2017","unstructured":"Curti V, Di Lorenzo A, Dacrema M, Xiao J, Nabavi SM, Daglia M (2017) In vitro polyphenol effects on apoptosis: an update of literature data. Semin Cancer Biol 46:119\u2013131. https:\/\/doi.org\/10.1016\/j.semcancer.2017.08.005","journal-title":"Semin Cancer Biol"},{"key":"2802_CR64","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00432-014-1640-4","volume":"140","author":"C Palmeira-dos-Santos","year":"2014","unstructured":"Palmeira-dos-Santos C, Pereira GJ, Barbosa CM, Jurkiewicz A, Smaili SS, Bincoletto C (2014) Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine-induced death of leukaemia cells. J Cancer Res Clin Oncol 140:909\u2013920","journal-title":"J Cancer Res Clin Oncol"},{"key":"2802_CR65","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1023\/A:1020647211557","volume":"7","author":"DC Dartsch","year":"2002","unstructured":"Dartsch DC, Schaefer A, Boldt S, Kolch W, Marquardt H (2002) Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis 7:537\u2013548","journal-title":"Apoptosis"},{"key":"2802_CR66","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/sj.leu.2401803","volume":"14","author":"MA Belaud-Rotureau","year":"2000","unstructured":"Belaud-Rotureau MA, Durrieu F, Labroille G, Lacombe F, Fitoussi O, Agape P, Belloc F (2000) Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. Leukemia 14:1266\u20131275","journal-title":"Leukemia"},{"key":"2802_CR67","first-page":"4439","volume":"33","author":"M Stojak","year":"2013","unstructured":"Stojak M, Mazur L, Opydo-Chanek M, \u0141ukawska M, Oszczapowicz I (2013) In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin. Anticancer Res 33:4439\u20134443","journal-title":"Anticancer Res"}],"container-title":["Biological Trace Element Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12011-021-02802-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12011-021-02802-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12011-021-02802-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T11:47:34Z","timestamp":1699184854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12011-021-02802-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1007\/s12011-021-02802-2","relation":{},"ISSN":["0163-4984","1559-0720"],"issn-type":[{"value":"0163-4984","type":"print"},{"value":"1559-0720","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This is an in vitro study, which does not include any sample receiving process from human or animal. Human acute promyelocytic leukemia cell line (HL-60 cell line, RRID: CVCLA794) were obtained from ATCC\u00ae (CCL-240).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}